7 June 2022 - FORUS Therapeutics is pleased to announce that on 31 May 2022, Xpovio (selinexor) was authorised for sale by Health Canada in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Approval was based on the Phase 3 BOSTON trial of Xpovio in combination with once weekly bortezomib and low dose dexamethasone compared to twice-weekly bortezomib and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.

Read Forus Therapeutics press release